The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression — Abilify

Psychotic Depression Clinical Trial

Official title:
The Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in the Acute Treatment of Psychotic Major Depression: Efficacy and Tolerability

Status Completed

Clinical Trial Summary

The purpose of the study is to assess the safety and effectiveness of the combination of aripiprazole (Abilify) and selective serotonin reuptake inhibitors (SSRIs) in subjects with psychotic major depression.

Clinical Trial Description

n/a

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00556140
Study type	Interventional
Source	Massachusetts General Hospital
Contact
Status	Completed
Phase	Phase 3
Start date	June 2003
Completion date	January 2008

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06005766` - The Efficacy of Metacognitive Skills Training in the Context of Forensic Psychiatric Care	N/A
Completed	`NCT00751504` - Quetiapine in the Treatment of Psychotic Depression - a Pilot Study	Phase 3
Not yet recruiting	`NCT05034523` - Voxel Based Morphometry In Patients With Psychotic Versus Non Psychotic Depression
Completed	`NCT02782442` - Cognitive Training Delivered Remotely to Individuals With Psychosis (ROAM)	N/A
Completed	`NCT01427608` - Sustaining Remission of Psychotic Depression	Phase 4
Terminated	`NCT00637494` - A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features	Phase 3
Completed	`NCT00400166` - Recovery Guide Intervention for Recurrent Psychiatric Hospitalization	N/A